Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) approved for the treatment of patients with type 2 diabetes (T2D) who are not satisfactorily controlled through diet and exercise and other glucose-lowering medications1 and for weight management in adults with overweight or obesity2. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.